Moti Ramgopal

Moti Navindra Ramgopal (born August 27, 1965) is a Guyanese American Infectious Disease physician and clinical researcher who has contributed to research in HIV/AIDS, Hepatitis, COVID-19, and emerging infectious diseases. He is the founder and medical Director of Midway Immunology and Research Center and founder and chairman of the Midway Specialty Care Center. He also serves as a Clinical Professor of medicine at Florida State University (FSU), College of Medicine.

Early life and education

After earning his Bachelor of Medicine, Bachelor of Surgery (MBBS) degree in 1989 at the University of the West Indies (UWI), Mona Campus in Kingston, Jamaica.

Ramgopal left the Bahamas to complete his residency in internal medicine at Bon Se cours Hospital in Michigan, graduating in 1995. He then pursued a Fellowship in Infectious Diseases at Jackson Memorial Hospital and the University of Miami School of Medicine, completing it in 1997.

Research

As a clinical researcher, Ramgopal has participated in numerous Phase II, III, and IV clinical trials, in HIV/AIDS, Hepatitis-C, Mycobacterial infections, COVID-19, Vaccines, and emerging infectious diseases (Mpox). Ramgopal is published in peer-reviewed medical journals including The New England Journal of Medicine, The Lancet, Journal of the American Medical Association, and Clinical Infectious Diseases.

In 2023, Ramgopal was the lead primary investigator of the SOLAR study, the first head-to-head clinical trial comparing the long-acting injectable HIV regimen cabotegravir/rilpivirine (CABENUVA) with the daily oral drug bictegravir/emtricitabine/tenofovir alafenamide (BIKTARVY). The study evaluated the efficacy, safety, and patient-reported outcomes of both treatments. Its findings contributed to the understanding of long-acting injectable HIV therapy as an alternative to daily oral antiretrovirals.